Johnson & Johnson (JNJ)

$225.34 -2.16 (-0.95%)
Market Cap 547.64B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 21.50
Forward PE 19.93
Profit Margin 28.46%
Debt to Equity Ratio 0.48
Volume 7,897,800
Avg Vol 8,279,580
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 20%
Beta 0.34
Analysts Strong Sell
Price Target $259.50

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
Suite510
Suite510 Apr. 28 at 1:20 AM
$JNJ $SPX $SPY $ABT oh this almost looks like a JNJ type verdict, guessing a real bankruptcy still a possibility 🤷🤣 A jury in Georgia has ordered Monsanto parent Bayer to pay nearly $2.1 billion in damages to a man who says the company’s Roundup weed killer caused his cancer.
0 · Reply
NeoZerolag
NeoZerolag Apr. 27 at 11:16 PM
$FN $LCID $CAST $JNJ 7
0 · Reply
LiveCommander
LiveCommander Apr. 27 at 10:30 PM
Question: where's the math? Bullish narratives stacking on $IGV momentum and AI productivity ignore base-rate exhaustion signals 📊 Risk assessment: melt-up tape, but vol skew is cheap. Positioning advice: trim delta into strength, hedge via puts on $XLK, rotate to defensives like $PG, $JNJ for ballast.
0 · Reply
LiveCommander
LiveCommander Apr. 27 at 10:13 PM
Question: where's the actual price discovery edge here? Superforecaster consensus ≠ deep two-way liquidity. Until institutional flow validates these benchmarks, treat as signal, not hedge instrument. 🛡️ Stay sized small, demand wider spreads. $CME $ICE $JNJ
0 · Reply
_AceZerolag
_AceZerolag Apr. 27 at 10:00 PM
$IRDM $INFQ $JNJ $INTU mm
0 · Reply
DragonAlgo
DragonAlgo Apr. 27 at 9:57 PM
🐉 $JNJ PUT — DragonAlgo® Signal Contract: JNJ PUT Expiry: 2026-05-01 | Strike: $225.00 | Type: PUT Option Plan (premium): Entry: $2.29 Stop: $1.65 TP1: $2.97 TP2: $3.88 TP3: $5.48 🔗 https://dragonalgo.com
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Apr. 27 at 9:35 PM
Can you identify when a pullback is actually creating a high‑probability buy zone? $JNJ is heading into the 227.8–215.8 area, where buyers are expected to show up. Learn this skill and apply it to any market. Check out this 👉 https://elliottwave-forecast.com/stock-market/jnj-forecast-buyers-should-enter-227-8-215-8-area #elliottwave #stocks
0 · Reply
focafoca99
focafoca99 Apr. 27 at 9:13 PM
$JNJ received FDA Priority Review for IMAAVY in warm autoimmune hemolytic anemia. https://www.rapidticker.com/news/jnj-fda-grants-priority-review-for-09369e
0 · Reply
LiveCommander
LiveCommander Apr. 27 at 9:01 PM
Risk assessment: $C parabolic extension without volume confirmation flags exhaustion. Reward/risk skewed unfavorably at these levels 📊 Positioning advice: Trim into strength, trail stops below prior pivot. Rotate proceeds toward defensives like $JNJ or $PG. Chasing momentum here offers poor expectancy.
0 · Reply
TGZerolag
TGZerolag Apr. 27 at 8:38 PM
$INTU $MX $JNJ $SQM season
0 · Reply
Latest News on JNJ
Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 4:33 PM EDT - 4 hours ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 11:03 AM EDT - 10 hours ago

J&J sees AI halving the time to generate drug development leads

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Apr 27, 2026, 8:03 AM EDT - 13 hours ago

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Apr 24, 2026, 4:30 PM EDT - 3 days ago

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Cramer says look to these 4 stocks to go with your high-flying tech names

Apr 23, 2026, 6:44 PM EDT - 4 days ago

Cramer says look to these 4 stocks to go with your high-flying tech names

CAH CVS UNH

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Apr 22, 2026, 8:05 AM EDT - 5 days ago

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Apr 22, 2026, 4:00 AM EDT - 5 days ago

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Apr 21, 2026, 4:22 PM EDT - 6 days ago

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

Apr 21, 2026, 7:45 AM EDT - 6 days ago

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

Apr 17, 2026, 10:36 PM EDT - 9 days ago

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims

Apr 17, 2026, 7:00 PM EDT - 10 days ago

U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson

Apr 16, 2026, 10:16 AM EDT - 11 days ago

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson

LLY MGTX

Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

Apr 15, 2026, 4:11 PM EDT - 12 days ago

Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

These Analysts Boost Their Forecasts On Johnson & Johnson Following Strong Q1 Results

Apr 15, 2026, 1:43 PM EDT - 12 days ago

These Analysts Boost Their Forecasts On Johnson & Johnson Following Strong Q1 Results

Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst

Apr 15, 2026, 12:37 PM EDT - 12 days ago

Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst

Johnson & Johnson CFO on the company's robotic surgical system

Apr 14, 2026, 10:51 AM EDT - 13 days ago

Johnson & Johnson CFO on the company's robotic surgical system

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

Apr 14, 2026, 10:30 AM EDT - 13 days ago

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

ORCL BE KMX

J&J raises guidance for 2026 on strong start to the year

Apr 14, 2026, 6:55 AM EDT - 13 days ago

J&J raises guidance for 2026 on strong start to the year

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Apr 14, 2026, 6:25 AM EDT - 13 days ago

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

Apr 14, 2026, 6:21 AM EDT - 13 days ago

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

Apr 14, 2026, 6:20 AM EDT - 13 days ago

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Apr 14, 2026, 6:20 AM EDT - 13 days ago

J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Dow Jones Stocks In Spotlight: JPMorgan, Johnson & Johnson Among This Week's Earnings Reports

Apr 13, 2026, 11:36 AM EDT - 14 days ago

Dow Jones Stocks In Spotlight: JPMorgan, Johnson & Johnson Among This Week's Earnings Reports

JPM DIA TRV

Goldman Sachs, Bank of America, JP Morgan, Netflix, J&J, Producer Prices, and More to Watch This Week

Apr 12, 2026, 2:00 PM EDT - 15 days ago

Goldman Sachs, Bank of America, JP Morgan, Netflix, J&J, Producer Prices, and More to Watch This Week

NFLX BAC GS JPM

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Apr 10, 2026, 8:00 AM EDT - 17 days ago

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Apr 9, 2026, 7:57 AM EDT - 18 days ago

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Apr 8, 2026, 10:41 AM EDT - 19 days ago

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Apr 7, 2026, 8:00 AM EDT - 20 days ago

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Royalty Pharma and J&J partner to develop autoimmune treatment

Mar 30, 2026, 9:14 AM EDT - 4 weeks ago

Royalty Pharma and J&J partner to develop autoimmune treatment

RPRX

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Mar 28, 2026, 10:00 AM EDT - 4 weeks ago

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Mar 27, 2026, 4:46 PM EDT - 4 weeks ago

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Mar 27, 2026, 6:31 AM EDT - 4 weeks ago

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

The Big 3: ORCL, JNJ, SBUX

Mar 19, 2026, 1:00 PM EDT - 5 weeks ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

Mar 19, 2026, 9:35 AM EDT - 5 weeks ago

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 5 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK LLY

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Mar 18, 2026, 1:17 PM EDT - 5 weeks ago

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 8:31 AM EDT - 5 weeks ago

US FDA approves J&J's oral psoriasis pill

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Mar 18, 2026, 7:49 AM EDT - 5 weeks ago

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Mar 16, 2026, 11:00 AM EDT - 6 weeks ago

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Mar 13, 2026, 12:35 PM EDT - 6 weeks ago

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Mar 12, 2026, 8:00 AM EDT - 6 weeks ago

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 3:55 PM EST - 7 weeks ago

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

US FDA approves JNJ's blood cancer drug

Mar 5, 2026, 2:21 PM EST - 7 weeks ago

US FDA approves JNJ's blood cancer drug

Johnson & Johnson launches website for direct-to-consumer sales

Mar 4, 2026, 6:07 PM EST - 7 weeks ago

Johnson & Johnson launches website for direct-to-consumer sales

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Mar 3, 2026, 8:03 AM EST - 7 weeks ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Mar 2, 2026, 4:30 PM EST - 2 months ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 26, 2026, 2:30 PM EST - 2 months ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 24, 2026, 4:03 PM EST - 2 months ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 11:35 AM EST - 2 months ago

Does JNJ Stock Still Offer Value?

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:43 AM EST - 2 months ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Suite510
Suite510 Apr. 28 at 1:20 AM
$JNJ $SPX $SPY $ABT oh this almost looks like a JNJ type verdict, guessing a real bankruptcy still a possibility 🤷🤣 A jury in Georgia has ordered Monsanto parent Bayer to pay nearly $2.1 billion in damages to a man who says the company’s Roundup weed killer caused his cancer.
0 · Reply
NeoZerolag
NeoZerolag Apr. 27 at 11:16 PM
$FN $LCID $CAST $JNJ 7
0 · Reply
LiveCommander
LiveCommander Apr. 27 at 10:30 PM
Question: where's the math? Bullish narratives stacking on $IGV momentum and AI productivity ignore base-rate exhaustion signals 📊 Risk assessment: melt-up tape, but vol skew is cheap. Positioning advice: trim delta into strength, hedge via puts on $XLK, rotate to defensives like $PG, $JNJ for ballast.
0 · Reply
LiveCommander
LiveCommander Apr. 27 at 10:13 PM
Question: where's the actual price discovery edge here? Superforecaster consensus ≠ deep two-way liquidity. Until institutional flow validates these benchmarks, treat as signal, not hedge instrument. 🛡️ Stay sized small, demand wider spreads. $CME $ICE $JNJ
0 · Reply
_AceZerolag
_AceZerolag Apr. 27 at 10:00 PM
$IRDM $INFQ $JNJ $INTU mm
0 · Reply
DragonAlgo
DragonAlgo Apr. 27 at 9:57 PM
🐉 $JNJ PUT — DragonAlgo® Signal Contract: JNJ PUT Expiry: 2026-05-01 | Strike: $225.00 | Type: PUT Option Plan (premium): Entry: $2.29 Stop: $1.65 TP1: $2.97 TP2: $3.88 TP3: $5.48 🔗 https://dragonalgo.com
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Apr. 27 at 9:35 PM
Can you identify when a pullback is actually creating a high‑probability buy zone? $JNJ is heading into the 227.8–215.8 area, where buyers are expected to show up. Learn this skill and apply it to any market. Check out this 👉 https://elliottwave-forecast.com/stock-market/jnj-forecast-buyers-should-enter-227-8-215-8-area #elliottwave #stocks
0 · Reply
focafoca99
focafoca99 Apr. 27 at 9:13 PM
$JNJ received FDA Priority Review for IMAAVY in warm autoimmune hemolytic anemia. https://www.rapidticker.com/news/jnj-fda-grants-priority-review-for-09369e
0 · Reply
LiveCommander
LiveCommander Apr. 27 at 9:01 PM
Risk assessment: $C parabolic extension without volume confirmation flags exhaustion. Reward/risk skewed unfavorably at these levels 📊 Positioning advice: Trim into strength, trail stops below prior pivot. Rotate proceeds toward defensives like $JNJ or $PG. Chasing momentum here offers poor expectancy.
0 · Reply
TGZerolag
TGZerolag Apr. 27 at 8:38 PM
$INTU $MX $JNJ $SQM season
0 · Reply
Buy_SoFi
Buy_SoFi Apr. 27 at 7:34 PM
$TLTFF <---- 👀 More and more eyes on this gem. Don't get me wrong, there is still some de-risking to do but by that time I expect the price to be double or triple what it is today. Volume increasing daily which is nice to see $MRK $JNJ $IBRX $CGON
0 · Reply
maq34
maq34 Apr. 27 at 5:19 PM
$ATRC $JNJ $MDT $HIMS $PFE https://www.marketbeat.com/instant-alerts/filing-oak-harvest-investment-services-makes-new-148-million-investment-in-atricure-inc-atrc-2026-04-18/ https://www.marketbeat.com/instant-alerts/filing-oak-harvest-investment-services-makes-new-148-million-investment-in-atricure-inc-atrc-2026-04-18/
0 · Reply
EliteSignals1
EliteSignals1 Apr. 27 at 4:46 PM
$JNJ large-cap healthcare company with diversified revenue and defensive characteristics
0 · Reply
AltcoinsPumpAndDump2024
AltcoinsPumpAndDump2024 Apr. 27 at 4:45 PM
$JNJ what’s up with this pos?
0 · Reply
NRG8
NRG8 Apr. 27 at 4:17 PM
$CRWV $COIN $CRSP $LLY $JNJ
0 · Reply
Buy_SoFi
Buy_SoFi Apr. 27 at 3:01 PM
$TLTFF 👀Theralase Technologies: Ruvidar and Rutherin showing amazing results. NMIBS, MIBC, Lung, Brain, Pancreatic, Colorectal AND HSV treatment in the pipeline. One of the most promising biotech stock in the world today. $IBRX $MRK $JNJ $GILD
0 · Reply
maikl_211
maikl_211 Apr. 27 at 2:30 PM
$ORCL $XOM $JNJ $ASML $MA
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Apr. 27 at 11:20 AM
$JNJ Buyers looking to take control from daily #Bluebox to new high or at least 3 swings bounce The corrective pullback reach between 227.8 - 215.8 area and expect soon to turn higher to extend January-2025 rally in daily. Buyers at least get 3 swing rally or above 256 or higher. https://elliottwave-forecast.com/stock-market/jnj-forecast-buyers-should-enter-227-8-215-8-area/ #Elliottwave #JNJ
0 · Reply
Suite510
Suite510 Apr. 27 at 11:14 AM
$JNJ $SPX $SPY $ABT Rescheduled Talc mediation is today, whereas Junk n Junk has LOST every single talc trial since March 2025 rut ro lol 😂
0 · Reply
AnthonyTradingWithJesus
AnthonyTradingWithJesus Apr. 26 at 10:19 PM
$JNJ $BBAI $MSFT $MARA $INTC
0 · Reply
stockanalysis_
stockanalysis_ Apr. 26 at 3:18 PM
Biggest Pharmaceutical Stocks: $LLY $JNJ $ABBV $AZN $MRK Download this screener: https://stockanalysis.com/list/pharmaceutical-stocks/?ref=saveontrading
0 · Reply
DragonAlgo
DragonAlgo Apr. 26 at 1:39 PM
🐉 $JNJ PUT — DragonAlgo® Signal Contract: JNJ PUT Expiry: 2026-05-01 | Strike: $225.00 | Type: PUT Option Plan (premium): Entry: $1.76 Stop: $1.27 TP1: $2.29 TP2: $2.99 TP3: $4.22 🔗 https://dragonalgo.com
0 · Reply